Pediatric Ganciclovir / Valganciclovir PopPK (Pescovitz 2010)
Indication: Cytomegalovirus prophylaxis and treatment exposure assessment in pediatric transplant recipients
Interactive population PK simulator for IV ganciclovir and oral valganciclovir solution in pediatric transplant recipients. Ganciclovir is a guanosine analogue antiviral that inhibits CMV viral DNA polymerase after intracellular phosphorylation. Based on the Pescovitz et al. 2010 population PK model for CMV prophylaxis and treatment exposure assessment.
Drug Overview
Clinical Context
- Molecular Target
- Viral DNA polymerase (via intracellular ganciclovir triphosphate)
- Drug Class
- Antiviral — Nucleoside Analogue
- Therapeutic Area
- Transplant Infectious Disease / CMV
- Indication
- Cytomegalovirus prophylaxis and treatment exposure assessment in pediatric transplant recipients
- Route of Administration
- IV ganciclovir / Oral valganciclovir solution
Model Information
- Model Type
- Population PK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Pediatric Ganciclovir / Valganciclovir allows you to explore concentration-time profiles under different dosing scenarios. The underlying Population PK model characterizes the pharmacokinetics of this antiviral — nucleoside analogue following iv ganciclovir / oral valganciclovir solution administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Pediatric Ganciclovir / Valganciclovir PK simulator?
This is a free, interactive pharmacokinetic simulator for Pediatric Ganciclovir / Valganciclovir used in Cytomegalovirus prophylaxis and treatment exposure assessment in pediatric transplant recipients. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Pediatric Ganciclovir / Valganciclovir belong to?
Pediatric Ganciclovir / Valganciclovir is classified as a Antiviral — Nucleoside Analogue that targets Viral DNA polymerase (via intracellular ganciclovir triphosphate). It is used in the Transplant Infectious Disease / CMV therapeutic area.
What route of administration does this model simulate?
This simulator models IV ganciclovir / Oral valganciclovir solution administration of Pediatric Ganciclovir / Valganciclovir. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a Population PK model. This model characterizes the time-course of drug concentrations following dosing.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Ready to Simulate?
Launch the Pediatric Ganciclovir / Valganciclovir simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community